Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.8600
- TODAY'S CHANGE (%)0.1300 (3.4853%)
- Bid / Lots3.7700/ 8
- Ask / Lots3.9100/ 105
- Open / Previous Close3.7500 / 3.7300
- Day Range
- 52 Week Range
- Volume274,081
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 2307 | 3.7056 |
| 09:34 ET | 600 | 3.69 |
| 09:36 ET | 6465 | 3.73 |
| 09:45 ET | 1273 | 3.77 |
| 09:48 ET | 685 | 3.78 |
| 09:56 ET | 1448 | 3.77 |
| 09:57 ET | 800 | 3.7613 |
| 09:59 ET | 100 | 3.77 |
| 10:01 ET | 100 | 3.77 |
| 10:06 ET | 1182 | 3.77 |
| 10:08 ET | 300 | 3.77 |
| 10:10 ET | 232 | 3.7783 |
| 10:14 ET | 365 | 3.7782 |
| 10:15 ET | 524 | 3.76 |
| 10:19 ET | 400 | 3.77 |
| 10:21 ET | 1495 | 3.79 |
| 10:24 ET | 600 | 3.81 |
| 10:26 ET | 800 | 3.7819 |
| 10:28 ET | 200 | 3.81 |
| 10:30 ET | 100 | 3.81 |
| 10:33 ET | 428 | 3.798 |
| 10:35 ET | 134 | 3.81 |
| 10:37 ET | 200 | 3.81 |
| 10:42 ET | 200 | 3.81 |
| 10:44 ET | 2059 | 3.795 |
| 10:48 ET | 1060 | 3.785 |
| 10:50 ET | 450 | 3.785 |
| 10:51 ET | 200 | 3.785 |
| 10:55 ET | 805 | 3.8 |
| 10:57 ET | 266 | 3.805 |
| 11:00 ET | 1300 | 3.815 |
| 11:02 ET | 1005 | 3.83 |
| 11:04 ET | 2038 | 3.83 |
| 11:06 ET | 100 | 3.83 |
| 11:08 ET | 700 | 3.83 |
| 11:09 ET | 300 | 3.84 |
| 11:11 ET | 490 | 3.86 |
| 11:13 ET | 259 | 3.8599 |
| 11:15 ET | 2513 | 3.84 |
| 11:18 ET | 1410 | 3.84 |
| 11:20 ET | 300 | 3.84 |
| 11:22 ET | 100 | 3.845 |
| 11:24 ET | 350 | 3.845 |
| 11:26 ET | 100 | 3.845 |
| 11:33 ET | 300 | 3.85 |
| 11:36 ET | 100 | 3.85 |
| 11:38 ET | 1600 | 3.855 |
| 11:42 ET | 100 | 3.86 |
| 11:44 ET | 200 | 3.86 |
| 11:45 ET | 1401 | 3.855 |
| 11:47 ET | 300 | 3.87 |
| 11:49 ET | 200 | 3.87 |
| 11:51 ET | 300 | 3.88 |
| 11:54 ET | 3229 | 3.875 |
| 11:58 ET | 200 | 3.87 |
| 12:02 ET | 4308 | 3.865 |
| 12:07 ET | 200 | 3.8799 |
| 12:09 ET | 100 | 3.88 |
| 12:14 ET | 200 | 3.88 |
| 12:18 ET | 300 | 3.885 |
| 12:20 ET | 394 | 3.885 |
| 12:21 ET | 3992 | 3.87 |
| 12:23 ET | 130 | 3.865 |
| 12:25 ET | 200 | 3.865 |
| 12:27 ET | 200 | 3.865 |
| 12:32 ET | 100 | 3.865 |
| 12:36 ET | 2307 | 3.865 |
| 12:38 ET | 902 | 3.86 |
| 12:41 ET | 438 | 3.855 |
| 12:45 ET | 200 | 3.855 |
| 12:48 ET | 100 | 3.855 |
| 12:50 ET | 100 | 3.86 |
| 12:52 ET | 600 | 3.855 |
| 12:54 ET | 639 | 3.86 |
| 12:57 ET | 200 | 3.87 |
| 01:01 ET | 219 | 3.87 |
| 01:03 ET | 300 | 3.87 |
| 01:08 ET | 666 | 3.88 |
| 01:10 ET | 200 | 3.88 |
| 01:12 ET | 208 | 3.88 |
| 01:14 ET | 866 | 3.88 |
| 01:15 ET | 300 | 3.89 |
| 01:17 ET | 691 | 3.88 |
| 01:19 ET | 3189 | 3.87 |
| 01:21 ET | 250 | 3.8663 |
| 01:24 ET | 200 | 3.87 |
| 01:26 ET | 944 | 3.88 |
| 01:28 ET | 3267 | 3.88 |
| 01:30 ET | 100 | 3.89 |
| 01:32 ET | 100 | 3.89 |
| 01:33 ET | 698 | 3.89 |
| 01:35 ET | 540 | 3.88 |
| 01:37 ET | 100 | 3.88 |
| 01:44 ET | 843 | 3.885 |
| 01:46 ET | 586 | 3.89 |
| 01:48 ET | 3248 | 3.88 |
| 01:50 ET | 215 | 3.88 |
| 01:51 ET | 100 | 3.88 |
| 01:53 ET | 400 | 3.88 |
| 01:57 ET | 3512 | 3.85 |
| 02:00 ET | 100 | 3.85 |
| 02:02 ET | 388 | 3.85 |
| 02:06 ET | 300 | 3.85 |
| 02:08 ET | 100 | 3.85 |
| 02:09 ET | 200 | 3.86 |
| 02:11 ET | 342 | 3.85 |
| 02:13 ET | 588 | 3.85 |
| 02:18 ET | 200 | 3.85 |
| 02:20 ET | 100 | 3.85 |
| 02:22 ET | 100 | 3.85 |
| 02:24 ET | 165 | 3.86 |
| 02:26 ET | 8566 | 3.87 |
| 02:27 ET | 100 | 3.86 |
| 02:29 ET | 591 | 3.86 |
| 02:31 ET | 200 | 3.87 |
| 02:33 ET | 504 | 3.855 |
| 02:36 ET | 1186 | 3.855 |
| 02:38 ET | 1311 | 3.86 |
| 02:40 ET | 4901 | 3.845 |
| 02:42 ET | 1490 | 3.8428 |
| 02:44 ET | 1600 | 3.845 |
| 02:45 ET | 191 | 3.845 |
| 02:47 ET | 193 | 3.845 |
| 02:49 ET | 2609 | 3.83 |
| 02:58 ET | 393 | 3.835 |
| 03:00 ET | 137 | 3.84 |
| 03:03 ET | 3096 | 3.82 |
| 03:05 ET | 300 | 3.82 |
| 03:07 ET | 1314 | 3.83 |
| 03:12 ET | 200 | 3.84 |
| 03:16 ET | 104 | 3.8201 |
| 03:18 ET | 4060 | 3.84 |
| 03:23 ET | 678 | 3.82 |
| 03:25 ET | 212 | 3.85 |
| 03:27 ET | 1453 | 3.85 |
| 03:30 ET | 907 | 3.855 |
| 03:32 ET | 2608 | 3.855 |
| 03:34 ET | 709 | 3.86 |
| 03:36 ET | 500 | 3.86 |
| 03:38 ET | 116 | 3.86 |
| 03:39 ET | 1038 | 3.86 |
| 03:41 ET | 460 | 3.86 |
| 03:43 ET | 1078 | 3.87 |
| 03:45 ET | 1339 | 3.87 |
| 03:48 ET | 5703 | 3.87 |
| 03:50 ET | 205 | 3.87 |
| 03:52 ET | 339 | 3.87 |
| 03:54 ET | 11341 | 3.89 |
| 03:56 ET | 7900 | 3.86 |
| 03:57 ET | 3205 | 3.86 |
| 03:59 ET | 5194 | 3.86 |
May 29, 2024
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
May 8, 2024
May 6, 2024
DJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer, from 7:57AM ET on Monday May 06, 2024 by Dow Jones
7:57AM ET on Monday May 06, 2024 by Dow JonesDJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 6:48AM ET on Monday May 06, 2024 by Dow Jones
6:48AM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 229.3M | -7.6x | --- |
Design Therapeutics Inc | 228.8M | -3.9x | --- |
Eliem Therapeutics Inc | 224.3M | -14.4x | --- |
Opthea Ltd | 224.2M | -1.1x | --- |
XBiotech Inc | 220.8M | -7.2x | --- |
Acrivon Therapeutics Inc | 238.4M | -2.7x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
